BeiGene Showcases Promising Waldenström’s Macroglobulinemia Research at IWWM 2024
San Mateo, Calif. – BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology leader, announced its participation in the 12th International Workshop on Waldenström’s Macroglobulinemia (IWWM) held in Prague from Oct. 17-19. BeiGene will present new data on BRUKINSA® (zanubrutinib), BTK chimeric degradation activation compound (CDAC) degrader BGB-16673, and BCL2 inhibitor sonrotoclax.
Key insights include seven presentations, with Mehrdad Mobasher, M.D., M.P.H., Chief Medical Officer, Hematology at BeiGene, delivering a keynote titled “Innovating for Impact: How BeiGene is Advancing Products and Pipeline to Address Waldenström’s Macroglobulinemia and Beyond.”
Highlights from Presentations:
- BRUKINSA® (Zanubrutinib): New data from the ASPEN LTE1 extension study shows long-term efficacy and safety in patients switching from ibrutinib. Additional findings from Phase 2 studies reveal that patients intolerant to other BTK inhibitors had fewer adverse events when treated with BRUKINSA.
- BGB-16673: Preliminary Phase 1 results from the CaDAnCe-101 study suggest that this BTK CDAC degrader is well tolerated and demonstrates promising antitumor activity, even in heavily pretreated relapsed/refractory (R/R) patients, including those with BTK and CXCR4 mutations.
- Sonrotoclax: Phase 1 findings indicate a favorable safety profile and encouraging antitumor activity in heavily pretreated R/R Waldenström’s Macroglobulinemia (WM) patients. A Phase 2 trial is underway, assessing its effectiveness in patients previously treated with BTK inhibitors or anti-CD20 therapy.
Additional Research:
BeiGene will also share a Phase 3 ASPEN study analysis highlighting the faster resolution of peripheral neuropathy symptoms in patients treated with BRUKINSA compared to ibrutinib, as well as survey results revealing variability in the active monitoring of asymptomatic WM patients across the UK.
About Waldenström’s Macroglobulinemia (WM)
WM is a rare, incurable type of B-cell lymphoma affecting older adults, primarily in the bone marrow. It constitutes less than 2% of non-Hodgkin lymphomas, with an estimated incidence of three to five cases per million people annually.
About BRUKINSA®
BRUKINSA is a BTK inhibitor designed to provide sustained inhibition, addressing malignant B-cell proliferation in multiple cancer types. It is approved in the U.S. for chronic lymphocytic leukemia, Waldenström’s macroglobulinemia, and several other lymphomas.
About BeiGene
BeiGene is committed to making innovative cancer treatments more affordable and accessible worldwide. With a diverse therapeutic portfolio and over 10,000 global employees, BeiGene continues to drive advancements in oncology research.
For full prescribing information on BRUKINSA and to learn more about BeiGene’s pipeline, please visit their official site.
